UCB SA (OTCMKTS:UCBJY – Get Free Report) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totaling 42,361 shares, an increase of 183.2% from the August 31st total of 14,956 shares. Based on an average trading volume of 100,514 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the company’s shares are short sold.
UCB Stock Up 1.6%
Shares of UCB stock opened at $122.64 on Friday. The business has a 50-day simple moving average of $127.24 and a 200-day simple moving average of $139.00. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. UCB has a one year low of $115.19 and a one year high of $168.76.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on UCBJY. Barclays cut UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Zacks Research lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 16th. Finally, Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.
UCB Company Profile
UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.
Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.
UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.
Featured Stories
- Five stocks we like better than UCB
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
